ME02317B - Neuroprotekcija kod demijelinizacijskih bolesti - Google Patents
Neuroprotekcija kod demijelinizacijskih bolestiInfo
- Publication number
- ME02317B ME02317B MEP-2015-212A MEP21215A ME02317B ME 02317 B ME02317 B ME 02317B ME P21215 A MEP21215 A ME P21215A ME 02317 B ME02317 B ME 02317B
- Authority
- ME
- Montenegro
- Prior art keywords
- combination therapy
- accordance
- dmf
- intended
- interferon
- Prior art date
Links
- 208000016192 Demyelinating disease Diseases 0.000 title claims 2
- 230000004112 neuroprotection Effects 0.000 title 1
- 238000002648 combination therapy Methods 0.000 claims 15
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 claims 10
- 229960004419 dimethyl fumarate Drugs 0.000 claims 10
- NKHAVTQWNUWKEO-UHFFFAOYSA-N fumaric acid monomethyl ester Natural products COC(=O)C=CC(O)=O NKHAVTQWNUWKEO-UHFFFAOYSA-N 0.000 claims 7
- NKHAVTQWNUWKEO-NSCUHMNNSA-N monomethyl fumarate Chemical compound COC(=O)\C=C\C(O)=O NKHAVTQWNUWKEO-NSCUHMNNSA-N 0.000 claims 7
- 229940005650 monomethyl fumarate Drugs 0.000 claims 7
- 108010072051 Glatiramer Acetate Proteins 0.000 claims 6
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims 6
- 229960003776 glatiramer acetate Drugs 0.000 claims 6
- 108010005716 Interferon beta-1a Proteins 0.000 claims 4
- 229960004461 interferon beta-1a Drugs 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 4
- 108090000467 Interferon-beta Proteins 0.000 claims 3
- 102000003996 Interferon-beta Human genes 0.000 claims 3
- 229960001388 interferon-beta Drugs 0.000 claims 3
- 239000002552 dosage form Substances 0.000 claims 2
- 206010071068 Clinically isolated syndrome Diseases 0.000 claims 1
- 206010012305 Demyelination Diseases 0.000 claims 1
- 108010005714 Interferon beta-1b Proteins 0.000 claims 1
- 206010067063 Progressive relapsing multiple sclerosis Diseases 0.000 claims 1
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims 1
- 230000003376 axonal effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229960003161 interferon beta-1b Drugs 0.000 claims 1
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 claims 1
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (15)
1. Kombinacijska terapija koja se sastoji od (a) dimetil-fumarata (DMF) i/ili monometil-fumarata (MMF) i (b) glatiramer-acetata, naznačena time što je namijenjen upotrebi u liječenju subjekta koji ima multiplu sklerozu (MS).
2. Kombinacijska terapija namijenjena upotrebi u skladu s patentnim zahtjevom 1, naznačena time što na subjektu treba primijeniti 20 mg dnevno glatiramer-acetata.
3. Kombinacijska terapija namijenjena upotrebi u skladu s patentnim zahtjevom 1, naznačena time što na subjektu treba primijeniti manje od 20 mg dnevno glatiramer-acetata.
4. Kombinacijska terapija namijenjena upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što su DMF i/ili MMF i glatiramer-acetat namijenjeni upotrebi u (i) smanjivanju stope recidiva kod subjekta; ili (ii) smanjivanju demijeliniziranje i/ili smrt aksona kod subjekta.
5. Kombinacijska terapija namijenjena upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što su DMF i/ili MMF i glatiramer-acetat formulirani u isti oblik doziranja.
6. Kombinacijska terapija namijenjena upotrebi u skladu s bilo kojim od patentnim zahtjevima 1 do 4, naznačena time što su DMF i/ili MMF i glatiramer-acetat formulirani u odvojene oblike doziranja namijenjene primjeni odvojeno ili zajedno.
7. Kombinacijska terapija koja se sastoji od (a) DMF i/ili MMF i (b) interferona-β, naznačena time što je namijenjena upotrebi u liječenju subjekta koji ima MS.
8. Kombinacijska terapija namijenjena upotrebi u skladu s patentnim zahtjevom 7, naznačena time što se interferon-β bira između interferona-β1a i interferona-β1b.
9. Kombinacijska terapija namijenjena upotrebi u skladu s patentnim zahtjevom 8, naznačena time što je interferon-β interferon-β1a.
10. Kombinacijska terapija namijenjena upotrebi u skladu s patentnim zahtjevom 9, naznačena time što interferon-β1a treba primijeniti u dozi od 5 µg do 80 µg odjednom.
11. Kombinacijska terapija namijenjena upotrebi u skladu s patentnim zahtjevom 10, naznačena time što interferon-β1a treba primijeniti jednom tjedno.
12. Kombinacijska terapija namijenjena upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što se MS bira između recidivirajući remitirajući MS, sekundarni progresivni MS, primarni progresivni MS, progresivni recidivirajući MS, te klinički izolirani sindrom.
13. Kombinacijska terapija namijenjena upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što je spoj koji se bira između DMF, MMF i njihovih kombinacija DMF.
14. Kombinacijska terapija namijenjena upotrebi u skladu s patentnim zahtjevom 13, naznačena time što na subjektu treba odjednom primijeniti 240 mg DMF.
15. Kombinacijska terapija namijenjena upotrebi u skladu s patentnim zahtjevom 14, naznačena time što DMF na subjektu treba primijeniti dva puta dnevno (BID), što je ekvivalent ukupnoj dnevnoj dozi od 480 mg dnevno.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30432510P | 2010-02-12 | 2010-02-12 | |
| US32148610P | 2010-04-06 | 2010-04-06 | |
| PCT/US2011/024594 WO2011100589A1 (en) | 2010-02-12 | 2011-02-11 | Neuroprotection in demyelinating diseases |
| EP11742896.1A EP2533634B1 (en) | 2010-02-12 | 2011-02-11 | Neuroprotection in demyelinating diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02317B true ME02317B (me) | 2016-06-20 |
Family
ID=44368163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2015-212A ME02317B (me) | 2010-02-12 | 2011-02-11 | Neuroprotekcija kod demijelinizacijskih bolesti |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20130287732A1 (me) |
| EP (2) | EP2982371A1 (me) |
| DK (1) | DK2533634T3 (me) |
| ES (1) | ES2555279T3 (me) |
| HR (1) | HRP20151350T1 (me) |
| HU (1) | HUE025878T2 (me) |
| ME (1) | ME02317B (me) |
| PL (1) | PL2533634T3 (me) |
| PT (1) | PT2533634E (me) |
| RS (1) | RS54551B1 (me) |
| SI (1) | SI2533634T1 (me) |
| SM (1) | SMT201600014B (me) |
| WO (1) | WO2011100589A1 (me) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005023241A1 (en) | 2003-09-09 | 2005-03-17 | Fumapharm Ag | The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma |
| DK1799196T3 (en) | 2004-10-08 | 2016-08-15 | Forward Pharma As | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
| LT2653873T (lt) | 2007-02-08 | 2022-10-10 | Biogen Ma Inc. | Kompozicijos ir naudojimas, skirti išsėtinei sklerozei gydyti |
| US20100130607A1 (en) * | 2007-02-08 | 2010-05-27 | Ralf Gold | Neuroprotection in demyelinating diseases |
| CN109044985A (zh) | 2009-01-09 | 2018-12-21 | 前进制药知识产权有限公司 | 包含溶蚀骨架中的一种或多种富马酸酯的药物制剂 |
| US9422226B2 (en) | 2011-06-08 | 2016-08-23 | Biogen Ma Inc. | Process for preparing high purity and crystalline dimethyl fumarate |
| US9504679B2 (en) | 2011-12-19 | 2016-11-29 | Bjoern Colin Kahrs | Pharmaceutical compositions comprising glitazones and Nrf2 activators |
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| MX370785B (es) | 2012-02-07 | 2020-01-06 | Biogen Ma Inc | Composiciones farmacéuticas que contienen fumarato de dimetilo. |
| US20130259856A1 (en) * | 2012-03-27 | 2013-10-03 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
| EP2692343A1 (en) * | 2012-08-03 | 2014-02-05 | Forward Pharma A/S | Combination therapy for treatment of multiple sclerosis |
| JP2015527372A (ja) * | 2012-08-22 | 2015-09-17 | ゼノポート，インコーポレイティド | 副作用を低減させるモノメチルフマレートおよびそのプロドラッグの投与方法 |
| AU2013305684B2 (en) | 2012-08-22 | 2016-11-24 | Xenoport, Inc. | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof |
| UA119032C2 (uk) * | 2012-10-02 | 2019-04-25 | Женеро Са | Фармацевтична композиція для лікування блокади ремієлінізації при захворюваннях, які пов'язані з експресією білка оболонки herv-w |
| AR094277A1 (es) | 2012-12-21 | 2015-07-22 | Biogen Idec Inc | Derivados de fumarato sustituidos con deuterio |
| US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
| PT2970101T (pt) | 2013-03-14 | 2018-10-04 | Alkermes Pharma Ireland Ltd | Pró-fármacos de fumaratos e seu uso no tratamento de várias doenças |
| WO2014160633A1 (en) | 2013-03-24 | 2014-10-02 | Xenoport, Inc. | Pharmaceutical compositions of dimethyl fumarate |
| US9421182B2 (en) | 2013-06-21 | 2016-08-23 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
| EP3041467A1 (en) | 2013-09-06 | 2016-07-13 | XenoPort, Inc. | Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use |
| WO2015105757A1 (en) * | 2014-01-07 | 2015-07-16 | Biogen Ma Inc. | Dimethyl fumarate for treating multiple sclerosis |
| EP3110793B1 (en) | 2014-02-24 | 2019-08-21 | Alkermes Pharma Ireland Limited | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases |
| US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
| MA40982A (fr) * | 2014-11-19 | 2017-09-26 | Biogen Ma Inc | Formulation de bille pharmaceutique comprenant du fumarate de diméthyle |
| MA41785A (fr) | 2015-03-20 | 2018-01-23 | Biogen Ma Inc | Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| LT3506921T (lt) | 2016-08-31 | 2023-08-10 | Mapi Pharma Ltd | Ilgesnio atpalaidavimo sistemos, kuriose yra glatiramero acetato |
| AU2018242998B2 (en) | 2017-03-26 | 2023-11-02 | Mapi Pharma Ltd. | Glatiramer depot systems for treating progressive forms of multiple sclerosis |
| US11382889B2 (en) * | 2018-04-19 | 2022-07-12 | Institut D'investigació Biomèdica De Bellvitge (Idibell) | NRF2 activators for the prevention and/or treatment of axonal degeneration |
| US11446055B1 (en) | 2018-10-18 | 2022-09-20 | Lumoptik, Inc. | Light assisted needle placement system and method |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19721099C2 (de) | 1997-05-20 | 1999-12-02 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten |
| DK1121382T3 (da) * | 1998-10-16 | 2006-11-13 | Biogen Idec Inc | Interferon-beta-fusionsproteiner og deres anvendelser |
| DE19853487A1 (de) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| DK1799196T3 (en) | 2004-10-08 | 2016-08-15 | Forward Pharma As | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
| WO2007006307A2 (en) * | 2005-07-07 | 2007-01-18 | Aditech Pharma Ab | Novel salts of fumaric acid monoalkylesters and their pharmaceutical use |
| US20080089861A1 (en) | 2006-07-10 | 2008-04-17 | Went Gregory T | Combination therapy for treatment of demyelinating conditions |
| US20100130607A1 (en) | 2007-02-08 | 2010-05-27 | Ralf Gold | Neuroprotection in demyelinating diseases |
| US20090104142A1 (en) * | 2007-10-17 | 2009-04-23 | Txcell | Compositions for treating multiple sclerosis |
-
2011
- 2011-02-11 DK DK11742896.1T patent/DK2533634T3/en active
- 2011-02-11 PL PL11742896T patent/PL2533634T3/pl unknown
- 2011-02-11 EP EP15184650.8A patent/EP2982371A1/en not_active Withdrawn
- 2011-02-11 EP EP11742896.1A patent/EP2533634B1/en not_active Revoked
- 2011-02-11 ME MEP-2015-212A patent/ME02317B/me unknown
- 2011-02-11 HU HUE11742896A patent/HUE025878T2/en unknown
- 2011-02-11 SI SI201130693T patent/SI2533634T1/sl unknown
- 2011-02-11 ES ES11742896.1T patent/ES2555279T3/es active Active
- 2011-02-11 RS RS20160028A patent/RS54551B1/sr unknown
- 2011-02-11 WO PCT/US2011/024594 patent/WO2011100589A1/en not_active Ceased
- 2011-02-11 HR HRP20151350TT patent/HRP20151350T1/hr unknown
- 2011-02-11 PT PT117428961T patent/PT2533634E/pt unknown
-
2013
- 2013-03-25 US US13/850,240 patent/US20130287732A1/en not_active Abandoned
-
2016
- 2016-01-15 SM SM201600014T patent/SMT201600014B/it unknown
- 2016-03-01 US US15/057,836 patent/US20160250172A1/en not_active Abandoned
-
2017
- 2017-07-07 US US15/644,029 patent/US20180021288A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2533634A4 (en) | 2013-07-10 |
| HRP20151350T1 (hr) | 2016-01-01 |
| US20130287732A1 (en) | 2013-10-31 |
| SMT201600014B (me) | 2016-02-25 |
| HUE025878T2 (en) | 2016-05-30 |
| SI2533634T1 (sl) | 2016-01-29 |
| US20180021288A1 (en) | 2018-01-25 |
| US20160250172A1 (en) | 2016-09-01 |
| EP2982371A1 (en) | 2016-02-10 |
| PT2533634E (pt) | 2015-12-28 |
| HK1179116A1 (en) | 2013-09-27 |
| EP2533634B1 (en) | 2015-10-21 |
| RS54551B1 (sr) | 2016-06-30 |
| ES2555279T3 (es) | 2015-12-30 |
| EP2533634A1 (en) | 2012-12-19 |
| DK2533634T3 (en) | 2016-01-25 |
| PL2533634T3 (pl) | 2016-04-29 |
| WO2011100589A1 (en) | 2011-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02317B (me) | Neuroprotekcija kod demijelinizacijskih bolesti | |
| HRP20220902T3 (hr) | Pripravci i njihova upotreba u liječenju multiple skleroze | |
| ME02282B (me) | Tretman multiple skleroze lakvinimodom | |
| JP2015038135A5 (me) | ||
| HRP20130057T1 (hr) | Lijeäśenje progresivne neurodegenerativne bolesti ibudilastom | |
| HRP20140102T1 (hr) | Cjepivo za prevenciju relapsa raka dojke | |
| ME02662B (me) | Niskofrekventna terapija glatiramer acetatom | |
| JP2013231087A5 (me) | ||
| JP2012046518A5 (me) | ||
| JP2010248207A5 (me) | ||
| MX2010005676A (es) | Metodo para retrasar el comienzo de esclerosis multiple clinicamente definida. | |
| HRP20161233T1 (hr) | Neurozaštita u demijelinizirajućim bolestima | |
| WO2009033792A3 (en) | Gamma 1 msh alone or in combination with pentagastrin as a therapeutic agent | |
| JP2007515469A5 (me) | ||
| JP2010525050A5 (me) | ||
| HRP20161280T1 (hr) | Farmaceutski pripravci | |
| JP2022188083A5 (me) | ||
| RU2014127298A (ru) | Применения иммуноконъюгатов, мишенью которых является cd138 | |
| RU2013148779A (ru) | Лечение инфекции вируса гепатита в по отдельности или в комбинации с вирусом гепатита дельта и родственных заболеваний печени | |
| JP2007238598A5 (me) | ||
| JP2020533302A5 (me) | ||
| IL276194B2 (en) | Pharmaceutical compounds or preparations containing them for use in the treatment of pain | |
| IL292770A (en) | Formulations and doses of pegylated uricase | |
| HRP20210010T1 (hr) | Injekcijske farmaceutske formulacije lefamulina | |
| JP2022028975A5 (me) |